Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
11.76 USD | -1.18% | -2.46% | -34.35% |
Financials (USD)
Sales 2024 * | 1.54M | Sales 2025 * | 5.81M | Capitalization | 718M |
---|---|---|---|---|---|
Net income 2024 * | -201M | Net income 2025 * | -241M | EV / Sales 2024 * | 231 x |
Net cash position 2024 * | 362M | Net cash position 2025 * | 377M | EV / Sales 2025 * | 58.7 x |
P/E ratio 2024 * |
-3.61
x | P/E ratio 2025 * |
-3.29
x | Employees | 158 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.29% |
Latest transcript on Pliant Therapeutics, Inc.
1 day | -4.95% | ||
1 week | -7.47% | ||
Current month | -20.13% | ||
1 month | -18.77% | ||
3 months | -31.37% | ||
6 months | -12.82% | ||
Current year | -34.29% |
Managers | Title | Age | Since |
---|---|---|---|
Bernard Coulie
CEO | Chief Executive Officer | 58 | 16-01-31 |
- | - | ||
Keith Cummings
DFI | Director of Finance/CFO | 47 | 18-11-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 21-01-11 |
Suzanne Bruhn
BRD | Director/Board Member | 60 | 16-06-30 |
Gayle Crowell
BRD | Director/Board Member | 73 | 20-01-07 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.16% | 2 M€ | -.--% | ||
0.08% | 0 M€ | 0.00% | - | |
0.07% | 237 M€ | +1.49% | - | |
0.07% | 0 M€ | 0.00% | - | |
0.05% | 7 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 11.89 | -0.08% | 246 660 |
24-04-24 | 11.9 | -4.95% | 368,691 |
24-04-23 | 12.52 | -0.63% | 243,871 |
24-04-22 | 12.6 | +0.64% | 211,566 |
24-04-19 | 12.52 | +2.71% | 306,228 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.29% | 718M | |
+25.61% | 660B | |
+23.01% | 562B | |
-5.24% | 358B | |
+16.49% | 322B | |
+8.28% | 297B | |
+12.79% | 219B | |
-9.57% | 196B | |
+6.66% | 199B | |
-8.75% | 149B |
- Stock Market
- Equities
- PLRX Stock